SCHEMBL1875372

SCHEMBL1875372

COc1cc2nccc(Oc3ccc(NC(=O)NC(=O)CCl)cc3Cl)c2cc1OC

nearest known ligand 0.67

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
KDR P35968 17/20 0.67
PDGFRA P16234 17/20 0.67
MET P08581 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1870323 0.89 KDR (0.62) KDRPDGFRAMET
SCHEMBL1878400 0.88 KDR (0.61) KDRPDGFRAMET
SCHEMBL1881037 0.88 MET (0.68) KDRPDGFRAMET
SCHEMBL1878994 0.88 PDGFRA (0.77) KDRPDGFRA
SCHEMBL13992603 0.87 PDGFRA (0.63) KDRPDGFRAMET
SCHEMBL1871327 0.87 MET (0.69) KDRPDGFRAMET
SCHEMBL1883436 0.87 PDGFRA (0.60) KDRPDGFRAMET
SCHEMBL1877704 0.87 PDGFRA (0.60) KDRPDGFRAMET
SCHEMBL1877706 0.87 KDR (0.60) KDRPDGFRAMET
SCHEMBL1874460 0.87 PDGFRA (0.69) KDRPDGFRAMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2258366-B1 Quinoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same KIRIN PHARMA KK (JP) 2013-04-03 EP disclosed
US-8324245-B2 Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-12-04 US disclosed
US-20110105747-A1 QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF-PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2011-05-05 US disclosed
EP-2258366-A2 Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same Kirin Pharma Kabushiki Kaisha (JP) 2010-12-08 EP disclosed
EP-1411046-B1 QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF-PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME KIRIN PHARMA KK (JP) 2009-09-16 EP disclosed
EP-2088141-A2 Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same Kirin Pharma Kabushiki Kaisha (JP) 2009-08-12 EP disclosed
US-20080312221-A1 QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF-PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2008-12-18 US disclosed
US-7425564-B2 Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus prolifertor receptor and medicinal composition containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2008-09-16 US disclosed
US-20040242603-A1 Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same KIRIN HOLDINGS KABUSHIKI KAISHA (JP) 2004-12-02 US disclosed
EP-1411046-A1 QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF−PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2004-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242603-A1 Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same NR1H2, NR1H3, NR1H4 KDR 1874/4885PDGFRA 1364/4885MET 72/4885
US-20080312221-A1 QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF-PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME NR1H2, NR1H3, NR1H4 KDR 3100/4885PDGFRA 1825/4885MET 320/4885
US-20110105747-A1 QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF-PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME NR1H2, NR1H3, NR1H4 KDR 2963/4885PDGFRA 1768/4885MET 306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.